NXL vs. INFU, TLSI, SGHT, ZJYL, STIM, LNSR, ECOR, PDEX, EDAP, and FONR
Should you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include InfuSystem (INFU), TriSalus Life Sciences (TLSI), Sight Sciences (SGHT), Jin Medical International (ZJYL), Neuronetics (STIM), LENSAR (LNSR), electroCore (ECOR), Pro-Dex (PDEX), Edap Tms (EDAP), and FONAR (FONR). These companies are all part of the "medical equipment" industry.
Nexalin Technology vs.
InfuSystem (NYSE:INFU) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
InfuSystem presently has a consensus target price of $13.00, indicating a potential upside of 69.93%. Nexalin Technology has a consensus target price of $3.00, indicating a potential upside of 4.53%. Given InfuSystem's stronger consensus rating and higher probable upside, research analysts plainly believe InfuSystem is more favorable than Nexalin Technology.
InfuSystem received 5 more outperform votes than Nexalin Technology when rated by MarketBeat users. Likewise, 100.00% of users gave InfuSystem an outperform vote while only 50.00% of users gave Nexalin Technology an outperform vote.
InfuSystem has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.2, suggesting that its share price is 320% more volatile than the S&P 500.
InfuSystem has a net margin of 1.12% compared to Nexalin Technology's net margin of -3,407.98%. InfuSystem's return on equity of 2.78% beat Nexalin Technology's return on equity.
InfuSystem has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nexalin Technology had 2 more articles in the media than InfuSystem. MarketBeat recorded 2 mentions for Nexalin Technology and 0 mentions for InfuSystem. Nexalin Technology's average media sentiment score of 1.11 beat InfuSystem's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.
71.1% of InfuSystem shares are held by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are held by institutional investors. 10.2% of InfuSystem shares are held by insiders. Comparatively, 24.0% of Nexalin Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
InfuSystem beats Nexalin Technology on 13 of the 18 factors compared between the two stocks.
Get Nexalin Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nexalin Technology Competitors List
Related Companies and Tools
This page (NASDAQ:NXL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NXL Stock Alerts